Neuronet - Efficiently Networking European Neurodegeneration Research

          Newsletter 1 - September 19, 2019

Welcome to the first
issue of the Neuronet newsletter! 

Neuronet is a collaborative effort to improve collaboration and exploit synergies across some of the key research projects tackling neurodegenerative disorders in the world today.

Our programme actively connects 15 research projects, encompassing more than EUR 280 million of funding. All of these projects have been launched by the Innovative Medicines Initiative, Europe's biggest public and private partnership in the life sciences.

We are particularly proud to invite you to our Neuronet networking event where we will highlight these projects at this years' Alzheimer Europe Conference on 23-25 October in The Hague.

This and the future newsletter issues will introduce you to our fantastic
early-career researchers and investigators, project achievements as well as our activities.
Carlos Díaz
Neuronet Project Coordinator
CEO, SYNAPSE Research Management Partners
Lennert Steukers
Neuronet Project Leader
Manager, Clinical Scientist, Janssen Pharmaceutica NV



Spotlight on early-career investigators: an interview with Benjamin Falcon

Dr Benjamin Falcon is a postdoctoral scientist at the UK Medical Research Council Laboratory of Molecular Biology working on the IMPRiND project.
Read more

Scientific Coordination Board meeting brings together project leaders

Neuronet’s high-level, overarching Scientific Coordination Board is formed by leaders of 15 EU research projects in the area of neurodegeneration.
Read more

3D tool - landscape of European data availability for AD research

ROADMAPs interactive ‘heat map’ assessment visualises different European data sources and what Alzheimer's disease related outcomes they capture.
Read more

Scientists unveil plans to identify common social and cognitive elements in patients with Alzheimer’s disease, depression and schizophrenia

European scientists have mapped out a potentially radical new way to identify the causes of serious mental health conditions. The industry/academia PRISM consortium has developed a comprehensive plan, which aims to identify common links between Alzheimer’s disease, depression, and schizophrenia. Find out more about the PRISM project by watching this video.
Read more



EU research collaboration in Alzheimer’s disease & beyond

Neuronet's annual networking and communication event will highlight Innovative Medicine Initiative projects that work in the area of neurodegeneration research. The event will take place at the Alzheimer Europe Conference in The Hague. Registrations close on Sunday 13 October 2019.
Read more

Neuronet project newsletters

Amyloid imaging to prevent Alzheimer's disease Newsletter
August 2019 (AMYPAD)

We are so pleased to announce a major milestone in our AMYPAD program. The Diagnostic and Patient Management Study (DPMS) has reached the 50% recruitment mark.
European Prevention of Alzheimer's Dementia Newsletter
August 2019 (EPAD)

We are pleased to let you know that the EPAD project, originally scheduled to end in December 2019, has been extended for six months since the launch of its latest newsletter.
A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
August 2019 (PD-MitoQuant)

There is growing evidence that mitochondrial dysfunction is involved in Parkinson’s, but no effective treatments have been developed based on this knowledge.
European Quality In Preclinical Data Newsletter
July 2019 (EQIPD)

Have you been scorched by this year’s summer heat all over Europe already? Here are more hot summer-news from the EQIPD project.
Remote Assessment of Disease and Relapse Newsletter
June 2019 (RADAR-CNS)

Participant numbers have continued to grow, and there now is a total of 923 participants across the RADAR-CNS project.

What we are talking about


Our programme is well represented on Twitter with updates from 13 projects. Check it out to stay ahead on news about European neurodegeneration research. We also launched a campaign on social media on why we do what we do. Check out the hashtag #WeAreNeuronet
Twitter feed


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Newsletter 1 - September 19, 2019

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp